PRIMA BIOMED
Prima BioMed is a globally active leader in the development of personalized immunocellular therapeutic products for the treatment of cancer. Prima BioMed is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders. Prima‘s lead product is CVac™, an autologous dendritic cell-based product currently in clinical trials for ovarian cancer patients in remission, and soon starting a pilot trial for resected pancreatic cancer. Prima BioMed is listed on the Australian stock exchange, on the NASDAQ in the US and in Germany on the Deutsche Börse in an entry standard.
PRIMA BIOMED
Industry:
Biotechnology Pharmaceutical Therapeutics
Founded:
2001-01-01
Address:
Sydney, New South Wales, Australia
Country:
Australia
Website Url:
http://www.primabiomed.com.au
Total Employee:
11+
Status:
Closed
Contact:
+49 6139 8245254
Email Addresses:
[email protected]
Technology used in webpage:
Google Apps For Business All-Inkl
Similar Organizations
Prescient Therapeutics
Prescient Therapeutics is a biopharmaceutical company, discovers and develops novel immunotherapeutic products for the treatment of chronic.
Current Employees Featured
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2014-10-02 | Immutep | Immutep acquired by Prima Biomed | 28 M USD |
Official Site Inspections
http://www.primabiomed.com.au
- Host name: dd51818.kasserver.com
- IP address: 85.13.130.203
- Location: Germany
- Latitude: 51.2993
- Longitude: 9.491
- Timezone: Europe/Berlin
